Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, de dosis-respuesta para evaluar la eficacia y la seguridad del metilfenidato OROS® de liberación prolongada (LP) (54 y 72 mg/día) en adultos con trastorno por déficit de atención e hiperactividad - Lamda 2
- Conditions
- déficit de atención e hiperactividad (TDAH)MedDRA version: 9.1Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorder
- Registration Number
- EUCTR2007-002111-82-ES
- Lead Sponsor
- Janssen-Cilag International N.V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 0
Subjects must satisfy the following criteria to be enrolled in the study:
1. Subjects can be male or female.
2. Subjects must be aged between 18 and 65 years, inclusive.
3. Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition (DSM-IV)1,60 and confirmed by the Conners’ Adult ADHD Diagnostic Interview for DSM-IV.
4. Described chronic course of ADHD symptomatology from childhood to adulthood, with some symptoms present before age 7 years and continue to meet DSM-IV criteria at the time of assessment. ADHD is not diagnosed if the symptoms are better accounted for by another psychiatric disorder (e.g. mood disorder (especially bipolar disorder), anxiety disorder, psychotic disorder, personality disorder).
5. CAARS score of = 24 as determined by investigator at screening visit.
6. Women must be postmenopausal since one year, surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent (at the discretion of the investigator), or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], male partner sterilization) before entry and continue to use the same method of contraception throughout the study.
7. Informed Consent Form signed by the subject.
8. Subject agrees to take only the supplied study drug as treatment for ADHD during the study.
9. Subject agrees not to initiate a new behavioral modification program during the study or if currently using a behavioral modification program and agrees not to change this program during the study.
10. Subject is able to comply with the study visit schedule and willing and able to complete the protocol-specified assessments.
11. Healthy on the basis of a physical examination, medical history and the results of blood biochemistry or hematology tests. If the results of the biochemistry or hematology tests are not within the laboratory's normal reference ranges, the subject may be included if the investigator considers the deviations are not clinically relevant. This should be clearly recorded in the subject's source documents and the Trial Manager informed.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
1. Known to be a non-responder to methylphenidate, or subject has a child known to be a non-responder to methylphenidate.
2. Has been treated with any methylphenidate-containing medication within 1 month of screening visit. One month is considered a reasonable time for patients treated with methylphenidate to return to a disease status baseline.
3. Participation in and premature withdrawal from 42603ATT3002 or 42603ATT3004 study.
4. Known allergy or hypersensitivity to methylphenidate, or components of PR OROS methylphenidate.
5. Any clinically unstable psychiatric condition including, but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), anti-social personality disorder, borderline personality disorder.
6. Subjects with a family history of schizophrenia or family history of affective psychosis.
7. Autism or Asperger’s syndrome.
8. Subjects with presence of motor tics, history of Tourette’s syndrome or family history of Tourette’s syndrome.
9. A diagnosis of substance use disorder (abuse/dependence) according to DSM-IV criteria within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary). Episodic abuse in the past is not an exclusion criterion.
10. Current eating disorder (e.g. bulimia, anorexia nervosa) or history of an eating disorder.
11. Known or suspected mental retardation.
12. Hyperthyroidism, myocardial infarction or stroke in the 6 months prior to screening for this study.
13. Subjects with history of seizures, glaucoma or uncontrolled hypertension.
14. Subjects with angina pectoris or cardiac arrhythmias
15. Pregnant or breast-feeding females.
16. Any co-existing medical condition or taking any concomitant medication that is likely to interfere with safe administration of methylphenidate including any herbal or homeopathic remedies; herbal and over-the-counter weight loss or diet preparations or drugs that contain stimulants.
17. Use of monoamine oxidase inhibitors, except if tapering off, within 4 weeks of the baseline visit.
18. Use of other anti-depressants (unless subject has been on a stable dosage for at least 3 months prior to screening, in which case treatment may continue so long as dosage remains unchanged for the duration of the study) or mood stabilizers (e.g. anti-epileptics, lithium), except if tapering off, within 2 weeks of the baseline visit (for fluoxetine within 4 weeks). Any medication likely to interfere with safe administration of methylphenidate.
19. Use of clonidine or other alpha-2 adrenergic receptor agonists, antipsychotic medications, theophylline, coumarin anticoagulants, anticonvulsants.
20. Subjects who have clinically significant gastrointestinal problems, including severe narrowing (pathologic or iatrogenic) of the gastrointestinal tract.
21. Subjects who are unable to swallow the study medication whole with the aid of liquids (participants may not chew, divide, dissolve or crush the study medication). 22. History of severe drug allergy or hypersensitivity.
23. Any serious illnesses including, but not limited to liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric or metabolic disturbances.
24. Confirmed cancer or malignancy.
25. Participation in an investigational drug trial in the 30 days prior
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method